scholarly journals Preparation and Evaluation of Sustained Release Venlafaxine HCl Microspheres

2015 ◽  
Vol 13 (1) ◽  
pp. 83-91
Author(s):  
Vinod Mokale ◽  
Jitendra Naik ◽  
Pankaj Wagh ◽  
Gokul Khairnar
Keyword(s):  
Side Effects ◽  
Sustained Release ◽  
Polymer Surface ◽  
Spherical Geometry ◽  
Release Formulation ◽  
Sustained Release Formulation ◽  
Eudragit Rs ◽  
Ft Ir ◽  
Preparation And Evaluation ◽  
Polymer Interaction

The aim of this study was to formulate and evaluate sustained release microsphere of Venlafaxine HCl (VF-HCl). It has many side effects with a half life around 5 hr. To reduce the adverse actions due to burst effect a sustained release (SR) Eudragit RS-100 microspheres embedded VF-HCl was formulated. The VF-HCl microspheres were prepared by oil in oil (O/O) solvent evaporation method. Drug and Polymer interaction for formulated SR Eudragit RS-100 microsphere embedded on VF-HCl was characterized by FT-IR and X-RD studie. The result showed that there is no interaction between the drug and polymer. Surface morphology of formulation carried out by FE-SEM … showed good spherical geometry and uniformity in size and shape. It can be concluded that the formulated VF-HCl microspheres using widely accepted O/O method and polymer were capable for exhibiting sustained release formulation with decreasing dosing frequency thereby minimizing the occurrence of side effects with improved bioavailability. DOI: http://dx.doi.org/10.3329/dujps.v13i1.21867 Dhaka Univ. J. Pharm. Sci. 13(1): 83-91, 2014 (June)

scholarly journals Liqui-Mass Technology as a Novel Tool to Produce Sustained Release Liqui-Tablet Made from Liqui-Pellets

Pharmaceutics ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1049
Author(s):  
Matthew Lam ◽  
Nour Nashed ◽  
Ali Nokhodchi
Keyword(s):  
Drug Release ◽  
Sustained Release ◽  
Tween 80 ◽  
Tween 20 ◽  
Release Formulation ◽  
Sustained Release Formulation ◽  
Eudragit Rs ◽  
Release Analysis ◽  
Insoluble Drugs ◽  
Eudragit Rs Po

The Liqui-Mass technology (also known as Liqui-Pellet technology) has shown promising results in terms of enhancing the drug release rate of water insoluble drugs in a simplistic approach. However, there is no current study on sustained-release formulation using the Liqui-Mass technology. In this study, an attempt was made to produce a sustained-release Liqui-Tablet for the first time using a matrix-based approach. The non-volatile co-solvent used in the investigation included Tween 80, Tween 20 and Kolliphor EL. The production of sustained-release propranolol hydrochloride Liqui-Tablet was successful, and data from the saturation solubility test and dissolution test did not show much difference among the mentioned non-volatile co-solvent. The best Liqui-Tablet formulation took 24 h for drug release to reach at around 100%. There seemed to be a synergistic retarding drug release effect when a non-volatile co-solvent and Eudragit RS PO were used together. The increase of Eudragit RS PO concentration increased the retardant effect. Kinetic drug release analysis suggests that the best formulation followed the Higuchi model. The flowability of pre-compressed Liqui-Tablet pellets had no issues and its size distribution was narrow. Liqui-Tablet was generally robust and most formulations passed the friability test. The study revealed that Liqui-Mass technology can be employed to sustain drug release.

scholarly journals Preparation and evaluation of novel galantamine hydrobromide sustained-release capsule

2016 ◽  
Vol 11 ◽  
pp. S82-S91 ◽  
Author(s):  
Shuoye Yang
Keyword(s):  
Sustained Release ◽  
In Vitro Release ◽  
In Vitro Study ◽  
Release Process ◽  
Release Formulation ◽  
Sustained Release Formulation ◽  
Promising Alternative ◽  
Release Studies ◽  
Preparation And Evaluation

In present study, a novel galantamine hydrobromide sustained-release capsule was prepared with the extrusion-spheronization method and the optimized preparative formulation. The release studies were performed using marketed capsules (Razadyne ER) as a reference and data were analyzed in terms of cumulative release amounts as a function of time. Furthermore, fiber-optic real time detection was adopted to monitor the release process. Results demonstrated that our developed formulation had superior properties, worked better as sustained-release carriers and lasted longer time to release compared with the marketed product. The in vitro release characteristics of different batches of preparations were quite similar with each other, the total release proportions of galantamine hydrobromide from sustained-release capsules reached higher than 90% within 12 hours. Similar factors f2 of two preparations were all higher than 50, the release profile of drugs from capsules fitted to Higuchi model with the equation of Q% = 0.2681t1/2 + 0.0684 (r = 0.9966). Pharmacokinetics profile and parameters in beagle dogs after oral administration also revealed the superior release performances of new capsules being consistent with the in vitro study. The developed sustained-release formulation may be a promising alternative dosage form for treatment of related diseases. 

Sign in / Sign up

Export Citation Format

Share Document